About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
Category Archives: OTC Switches
Adverse Events Reporting on OTCs and Supplements
As reported earlier this week, S.3546 – the Dietary and Supplement and Nonprescription Drug Consumer Act was passed by the Senate on December 6. Subsequently, on December 9, the House passed the Bill by a 2-1 majority. A few minutes … Continue reading
Posted in OTC Switches, Vitamins and Supplements
Comments Off on Adverse Events Reporting on OTCs and Supplements
Plan B Available OTC
Plan B will become available this week without a prescription, New York Newsday reports. It is about time. There are also reports that criticism has been voiced over the fact that the manufacturer has achieved exclusivity for a three year … Continue reading
Posted in OTC Switches
Comments Off on Plan B Available OTC
The Cold War
Recently Congressman Henry Waxman (D-CA) has been involved in correspondence with Acting Commissioner Andrew C. von Eschenbach. He wrote on August 23, September 22 and now again on October 23. It seems to be a monthly thing. His concern is … Continue reading
Posted in FDA Policy, OTC Switches
Comments Off on The Cold War
A Study of Statins
There is perhaps no better candidate in the pipeline for an RX to OTC switch than for statins. Statins lower cholesterol dramatically and therefore one can intuit – they would lower the rate of heart disease in this country if … Continue reading
Posted in OTC Switches
Comments Off on A Study of Statins
FDA, the Commissioner and Plan B
Apparently now it is being reported by the Minneapolis Star Tribune and Associated Press that Dr. Lester Crawford is stating that there was no attempt to disallow Plan B’s switch from RX to OTC, but rather that he delayed the … Continue reading
Posted in FDA Policy, OTC Switches
1 Comment